A pilot study of an intensified ganciclovir dosing strategy for treatment of cytomegalovirus disease in kidney and/or pancreas transplant recipients

Mathematical modeling suggests aggressive ganciclovir dosing in the first week of cytomegalovirus disease (CMV) treatment may improve response. This has not been evaluated clinically.

[1]  A. Humar,et al.  Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice , 2019, Clinical transplantation.

[2]  H. Hirsch,et al.  Cytomegalovirus sequence variability, amplicon length, and DNase-sensitive non-encapsidated genomes are obstacles to standardization and commutability of plasma viral load results. , 2018, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[3]  Deepali Kumar,et al.  Recurrence of CMV Infection and the Effect of Prolonged Antivirals in Organ Transplant Recipients , 2017, Transplantation.

[4]  A. Neumann,et al.  Novel decay dynamics revealed for virus-mediated drug activation in cytomegalovirus infection , 2017, PLoS pathogens.

[5]  E. Cordero,et al.  Viral load, CMV‐specific T‐cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[6]  R. Hayden,et al.  Clinical Utility of Viral Load in Management of Cytomegalovirus Infection after Solid Organ Transplantation , 2013, Clinical Microbiology Reviews.

[7]  A. Caliendo,et al.  Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  E. Cordero,et al.  Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations , 2013, Transplantation.

[9]  A. Burroughs,et al.  Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  T. Buclin,et al.  Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients , 2010, BMC infectious diseases.

[11]  B. Slobedman,et al.  Immunomodulatory Properties of a Viral Homolog of Human Interleukin-10 Expressed by Human Cytomegalovirus during the Latent Phase of Infection , 2008, Journal of Virology.

[12]  A. Kalil,et al.  Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes? , 2007, Clinical transplantation.

[13]  H Rollag,et al.  Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  Guy Boivin,et al.  Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. , 2002, The Journal of infectious diseases.

[15]  C. Sabin,et al.  Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation , 2000, The Lancet.

[16]  T. F. Smith,et al.  Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. , 2000, The Journal of infectious diseases.

[17]  G. Cathomas,et al.  Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. , 1999, The Journal of infectious diseases.

[18]  J. Gómez-Moreno,et al.  Infection in organ-transplant recipients. , 1998, The New England journal of medicine.

[19]  R. Boehme,et al.  Antiviral activity and mechanism of action of ganciclovir. , 1988, Reviews of infectious diseases.

[20]  V. Miller,et al.  Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  James L. McClelland,et al.  Meta‐analysis of brain‐derived neurotrophic factor p.Val66Met in adult ADHD in four European populations , 2010, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.